An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.

Chertin B, Spitz IM, Lindenberg T, Algur N, Zer T, Kuzma P, Young AJ, Catane R, Farkas A

The Journal of urology1 Mar 2000Cited by 24 (Europe PMC)

PMID10687989DOI10.1016/s0022-5347(05)67816-0PepBankPUB-10687989

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
In men with prostate cancer, clinical and biochemical responses were identical with one or two histrelin implants.
In plain wordsIn men with prostate cancer, one or two histrelin implants produced identical clinical and biochemical responses.
Peptide
Histrelin
Outcome
No significant changeClinical and biochemical response by implant number
Study
n = 15
Comparator
One versus two implants
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
60 microg daily per implant, one or two implants · subcutaneous implantAs given in this study (human).
Source sentences
Summary
The clinical and biochemical response was identical in those who received 1 or 2 implants.
2 context sentences(design, population, supporting numbers)
Summary · context
In an ongoing study we evaluated the effect of a long acting implant that releases the gonadotropin hormone-releasing hormone agonist histrelin ([ImBzl]D-His6,Pro9-Net) in 15 patients with disseminated prostate cancer.
Summary · context
The 2.6 cm. implant releasing 60 microg. histrelin daily is inserted subcutaneously into the upper arm using local anesthesia.
Report a problemFND-1068798907
02HumanNon-randomized trialEfficacy outcome
In the remaining 9 men treated for 21 to 30 months, LH remained completely suppressed with histrelin implants.
In plain wordsIn the remaining 9 men, histrelin maintained complete LH suppression during treatment lasting 21 to 30 months.
Peptide
Histrelin
Outcome
Not applicableLong-term LH suppression
Study
n = 9
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
60 microg daily per implant, one or two implants · subcutaneous implant · 21 to 30 monthsAs given in this study (human).
Source sentences
Summary
LH and testosterone remained completely suppressed and prostate specific antigen levels were in the normal range.
3 context sentences(design, population, supporting numbers)
Summary · context
Duration of treatment in the remaining 9 patients was between 21 and 30 months.
Summary · context
In an ongoing study we evaluated the effect of a long acting implant that releases the gonadotropin hormone-releasing hormone agonist histrelin ([ImBzl]D-His6,Pro9-Net) in 15 patients with disseminated prostate cancer.
Summary · context
The 2.6 cm. implant releasing 60 microg. histrelin daily is inserted subcutaneously into the upper arm using local anesthesia.
Report a problemFND-1068798904
03HumanNon-randomized trialEfficacy outcome
In the remaining 9 men treated for 21 to 30 months, testosterone remained completely suppressed with histrelin implants.
In plain wordsIn the remaining 9 men, histrelin maintained complete testosterone suppression during treatment lasting 21 to 30 months.
Peptide
Histrelin
Outcome
Not applicableLong-term testosterone suppression
Study
n = 9
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
60 microg daily per implant, one or two implants · subcutaneous implant · 21 to 30 monthsAs given in this study (human).
Source sentences
Summary
LH and testosterone remained completely suppressed and prostate specific antigen levels were in the normal range.
3 context sentences(design, population, supporting numbers)
Summary · context
Duration of treatment in the remaining 9 patients was between 21 and 30 months.
Summary · context
In an ongoing study we evaluated the effect of a long acting implant that releases the gonadotropin hormone-releasing hormone agonist histrelin ([ImBzl]D-His6,Pro9-Net) in 15 patients with disseminated prostate cancer.
Summary · context
The 2.6 cm. implant releasing 60 microg. histrelin daily is inserted subcutaneously into the upper arm using local anesthesia.
Report a problemFND-1068798905
04HumanNon-randomized trialEfficacy outcome
In the remaining 9 men treated for 21 to 30 months with histrelin implants, PSA levels were in the normal range.
In plain wordsIn the remaining 9 men receiving histrelin implants, PSA levels were in the normal range.
Peptide
Histrelin
Outcome
Not applicableLong-term PSA levels
Study
n = 9
Outcome group
Tumor growth · Cancer
Studied dose
60 microg daily per implant, one or two implants · subcutaneous implant · 21 to 30 monthsAs given in this study (human).
Source sentences
Summary
LH and testosterone remained completely suppressed and prostate specific antigen levels were in the normal range.
3 context sentences(design, population, supporting numbers)
Summary · context
Duration of treatment in the remaining 9 patients was between 21 and 30 months.
Summary · context
In an ongoing study we evaluated the effect of a long acting implant that releases the gonadotropin hormone-releasing hormone agonist histrelin ([ImBzl]D-His6,Pro9-Net) in 15 patients with disseminated prostate cancer.
Summary · context
The 2.6 cm. implant releasing 60 microg. histrelin daily is inserted subcutaneously into the upper arm using local anesthesia.
Report a problemFND-1068798906
05HumanNon-randomized trialMechanism
In eight men with prostate cancer receiving histrelin implants, LH remained completely suppressed during GnRH challenge, unlike untreated controls.
In plain wordsIn men with prostate cancer, LH remained completely suppressed during GnRH challenge with histrelin implants, unlike untreated controls.
Peptide
Histrelin
Outcome
DecreaseLH suppression during GnRH challenge
Study
n = 8
Comparator
Untreated controls recently diagnosed with prostate cancer
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
60 microg daily per implant, one or two implants · subcutaneous implantAs given in this study (human).
Source sentences
Summary
Unlike controls there was complete LH suppression in the 8 challenged patients.
3 context sentences(design, population, supporting numbers)
Summary · context
At 12 months 8 patients were challenged at intermittent intervals for up to 24 months with a bolus of 100 microg. gonadotropin hormone-releasing hormone followed by 2 weeks of flutamide.
Summary · context
The response was compared with that in untreated controls recently diagnosed with prostate cancer.
Summary · context
The 2.6 cm. implant releasing 60 microg. histrelin daily is inserted subcutaneously into the upper arm using local anesthesia.
Report a problemFND-1068798908
06HumanNon-randomized trialSafety outcome
One man with prostate cancer died of an unrelated cause 18 months after histrelin implant insertion.
In plain wordsOne man died of an unrelated cause 18 months after histrelin implant insertion.
Peptide
Histrelin
Outcome
Not applicableUnrelated death
Study
n: not reported in source
Outcome group
Mortality · Whole body
Studied dose
60 microg daily per implant, one or two implants · subcutaneous implantAs given in this study (human).
Source sentences
Summary
One patient requested implant removal after 1 year for personal reasons and 1 died of an unrelated cause 18 months after insertion.
2 context sentences(design, population, supporting numbers)
Summary · context
In an ongoing study we evaluated the effect of a long acting implant that releases the gonadotropin hormone-releasing hormone agonist histrelin ([ImBzl]D-His6,Pro9-Net) in 15 patients with disseminated prostate cancer.
Summary · context
The 2.6 cm. implant releasing 60 microg. histrelin daily is inserted subcutaneously into the upper arm using local anesthesia.
Report a problemFND-1068798902
07HumanNon-randomized trialEfficacy outcome
In men receiving histrelin implants, escape occurred in 4 cases at 5, 10, 12 and 19 months despite suppressed LH and testosterone.
In plain wordsIn men receiving histrelin implants, 'escape' was reported in 4 cases, although LH and testosterone stayed suppressed.
Peptide
Histrelin
Outcome
Not applicableEscape despite suppressed LH and testosterone
Study
n: not reported in source
Outcome group
Tumor growth · Cancer
Studied dose
60 microg daily per implant, one or two implants · subcutaneous implantAs given in this study (human).
Measurements
Cases with escape
4 cases
histrelin implant patients
Time of escape
5 months
case 1
Time of escape
10 months
case 2
Time of escape
12 months
case 3
Time of escape
19 months
case 4
Source sentences
Summary
Escape was demonstrated in 4 cases at 5, 10, 12 and 19 months, although LH and testosterone remained suppressed.
2 context sentences(design, population, supporting numbers)
Summary · context
In an ongoing study we evaluated the effect of a long acting implant that releases the gonadotropin hormone-releasing hormone agonist histrelin ([ImBzl]D-His6,Pro9-Net) in 15 patients with disseminated prostate cancer.
Summary · context
The 2.6 cm. implant releasing 60 microg. histrelin daily is inserted subcutaneously into the upper arm using local anesthesia.
Report a problemFND-1068798903

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.